(for review see Grunwald and Rosner, 1979) . The types of USA mutation responsible for treatment-related malignancies are not yet known (Povirk and Shuker, 1994) .
Monitoring patients treated with single antineoplastic
Manufacturing workers, nurses, pharmacists and other agents is aiding our understanding of what hazard these healthcare workers are potentially exposed to antineoplastic drugs pose in vivo. In this study, the frequency of mutant alkylating agents. Evidence is inconclusive as to whether this 6-thioguanine-resistant (TG R ) peripheral blood lymphoexposure is at a level that poses a genetic hazard to these cytes was monitored before treatment and for ≤35 weeks individuals. There are conflicting reports as to whether mutaafter treatment of patients with cyclophosphamide (CP) or genic activity is increased in the urine of healthcare workers chlorambucil (CAB). The mean mutant frequency before who handle cytotoxic drugs (Falck et al., 1979; Staiano et al. , treatment for six multiple sclerosis patients treated with 1981; Gibson et al., 1984; Venitt et al., 1984 ; Krepinsky high-dose CP was 2.53 ⍥ 10 -5 and increased after treatment et al., 1990) , although significant mutagenic activity has been to 4.61 ⍥ 10 -5 (P ⍧ 0.08, paired t-test). Using each patient detected in the urine of patients treated with cytotoxic drugs as their own control, there were significant increases (each (Eder et al., 1986; Peters et al., 1987; Krepinsky et al., 1990 ). at P < 0.04) detectable within 2-4 weeks in four of Significant increases in the frequency of 6-thioguanine-resistant the multiple sclerosis patients treated with CP. There was (TG R ) mutant lymphocytes have been observed in cancer no increase in an untreated control monitored over the patients treated with cytotoxic drugs (Dempsey et al., 1985) , same period. In a patient receiving five sequential CP in nurses and pharmacists working with cytotoxic drugs treatments at 1 month intervals, there were cumulative (Chrysostomou et al., 1984) and in workers involved in the increases in the frequency of mutant cells. The mutant manufacture of cyclophosphamide (Huttner et al., 1990) . A frequency increased from 0.31 ⍥ 10 -5 before treatment to review of occupational exposure to cytotoxic drugs suggests 3.64 ⍥ 10 -5 after the final treatment and had decreased to that, while there is evidence of potential hazardous exposure 0.53 ⍥ 10 -5 at 35 weeks after treatment. In one of via skin absorption, potential confounders need to be considered two CAB-treated patients with indolent non-Hodgkin's before a conclusion about the real hazard can be drawn (Sorsa lymphoma, there was a significant increase in mutant and Anderson, 1996) . frequency (P < 0.03) after treatment. Freshly isolated Studies of the frequencies of mutant cells from patients peripheral blood lymphocytes treated with 4-hydroperoxyexposed to multiple cytotoxic drugs are difficult to interpret CP in vitro demonstrate a dose-dependent increase in because the effect of each individual drug cannot be ascertained. mutant frequency. The increment in mutant frequency observed in vivo is of the order expected from the in vitro Although studies of exposure to a single drug are more experiments. Although this study demonstrates that single straightforward to evaluate, there are relatively few clinical or multiple doses of a single antineoplastic agent are situations where therapy with a single cytotoxic drug, rather mutagenic in vivo for some patients, further studies are than a combination of drugs, is indicated. Patients with severe needed to determine the extent and mechanism of the intersub-acute erythematosus and systemic lupus erythematosus individual variations in mutagenic response.
(SLE) are treated with cyclophosphamide (CP). Dawisha et al. (1994) found that treatment with CP did not correlate as strongly with mutant frequency as did total duration of active Introduction SLE disease. In a single-patient study, a significantly elevated frequency of TG R mutant cells has been observed (Wood et al., Cytotoxic alkylating agents are used clinically for treatment 1994) . Some patients with indolent non-Hodgkin's lymphomas of neoplastic diseases, as immunosuppressive agents in the are treated with chlorambucil (CAB) as a single agent and treatment of inflammatory connective tissue diseases and in some MS patients have been treated with CP as a single agent experimental therapies for multiple sclerosis (MS; Carter et al., during the chronic progressive stages of the disease (Carter 1988) . The genetic hazard posed by the use of alkylating et al., 1988) . CP requires activation to exert its activity agents has been recognized since at least the 1960s (Conen and (Benedict et al., 1977) . It undergoes metabolism, primarily in Lansky, 1961) and the occurrence of secondary malignancies the liver, to 4-hydroxy-CP, which spontaneously transforms to following treatment with alkylating agents is well documented.
aldophosphamide and then to phospharamide mustard and Treatment-related secondary leukemias have been reported acrolein (Shulman, 1993) . The initial metabolite of CP, following treatment for Hodgkin's disease (Tucker et al., 4-hydroxy-CP, is mutagenic and may be spontaneously trans-1988), breast cancer (Curtis et al., 1990) and ovarian cancer (Kaldor et al., 1990) . Acute myelogenous leukemia is the most formed to the phospharamide mustard metabolite intracellularly (Sanderson et al., 1991) . It is the phospharamide mustard T-lymphocyte cloning than normal controls (Palmer et al., Control cells were exposed to the appropriate volume of water or ether.
1988). One study found that cancer patients receiving CP had
Mutation assay procedure higher SCE frequencies than control untreated cancer patients
Mutation assays selecting for TG R cells were performed as previously (Jacobson-Kram et al., 1993) . Similarly, higher mutant frequendescribed (Morley et al., 1985) except that cells were cultured in RPMI with cies have been found in pediatric cancer patients treated with 10% fetal bovine serum (Hazelton) and 20% HL-1 medium (Ventrex).
CP (Sawada et al., 1998) . In contrast, elevated TG R frequencies
Medium was further supplemented with 20% LAK cell medium (a gift of
were not detected in CAB-treated patients (Palmer et al., Dr T.J.Eberline) or 20% Lymphocult-T (Biotest Diagnostics) as a source of interleukin-2. For each sample, mutation assays were performed on freshly 1986). Also, no significant increase in chromosome aberrations isolated lymphocytes and then repeated on batched cryopreserved lymphocytes were detected in CP-treated MS patients after treatment from the same blood sample. The in vitro dose-response experiments were (Ammenheuser et al., 1991) .
performed as described in Sanderson et al. (1991) . Briefly, cells were
The current study used each patient as their own control, resuspended at 0.5 ϫ 10 6 /ml, exposed to the drug for 1 h in RPMI/5% fetal bovine serum, washed six times and cultured for 10 days (to allow expression which was important because pre-treatment mutant frequency of induced mutations) before assaying mutant frequency. Statistical significance was expected to vary between individuals with MS. TG R in was determined by pooled or paired t-tests, as appropriate for the data.
T-lymphocytes is probably an indication that the cell has been activated in vivo, so it is not surprising that the frequency of Results TG R lymphocytes in patients with chronic progressive disease appears to correlate with clinical progression of the disease Experiments in this study were conducted over a period of 1 year. To monitor the reproducibility and reliability of the (Sriram, 1994) . CD45RO ϩ cells have a higher mutant frequency than CD45RA ϩ cells, suggesting that some subgroups of HPRT assay, a continuous cell line (WIL2-NS) was maintained and assayed over the same period. As shown in Table I , there T-lymphocytes are activated in vivo and undergo cellular division which may influence TG R frequency (Baars et al., was no significant change in mutant frequency for WIL2-NS over the period of these experiments 1995).
In this study we prospectively measured the frequency of The TG R mutant cell frequency was determined for six patients treated with high-dose (4.5-7.5 g) intravenous CP TG R lymphocytes before treatment and for ഛ35 weeks after treatment for six patients treated with single high doses of CP, administered over 9-15 days. Mutant frequency was determined for lymphocytes drawn immediately before treatment one patient who received five successive monthly treatments of lower dose CP and two patients treated with monthly CAB. and periodically in the months after treatment. Each patient served as his or her own control and the mean of multiple The induction of TG R cells in vivo was compared with the response of human cells to exposure to these two drugs in vitro.
determinations of mutant frequency before treatment was compared with the mean mutant frequency for the first post-4-Hydroperoxy-CP (4HCP), the synthetic precursor of 4-hydroxy-CP, was used for the in vitro studies. treatment samples obtained (at 2-4 weeks for all but one patient; see Table II ). The mean mutant frequency for the six patients was 2.53 ϫ 10 -5 before treatment and increased to Materials and methods 4.61 ϫ 10 -5 after treatment (P ϭ 0.076; paired t-test). When dose, reaching 10 times the pre-treatment level (P Ͻ 0.01),
Freshly isolated lymphocytes were in G 0 when harvested, but were stimulated and then declined over the 35 weeks after treatment (Figure 2 ).
into cycling by exposure to phytohemagglutinin before mutation assays.
Two patients with indolent non-Hodgkin's lymphoma were Lymphocytes were isolated and assayed at the hprt locus as detailed in Materials and methods. Values are the geometric mean Ϯ SD from three assays per patient.
In vitro exposure of freshly isolated lymphocytes to an active metabolite of CP, 4HCP, produced dose-dependent increases in the frequency of TG R mutants in the exposed cells. An equal exposure to 4HCP was two-to four-fold more mutagenic for the freshly isolated lymphocytes than for the lymphoblastoid cell line WIL2-NS (Figure 4) . A similar level of in vitro exposure to CAB has previously been shown to be mutagenic for the same lymphoblastoid cell line (Sanderson et al., 1991) .
Discussion
In this study, the number of TG R mutant T-lymphocytes in the peripheral blood of some treated patients increased after in vivo induce mutations in the hypoxanthine-guanine phosphoribosyl transferase (hprt) gene in vivo, manifest as significant increases in TG R mutant frequency in four of six CP-treated patients and one of two CAB-treated patients. Further evidence in (Figure 3 ). For one of the two patients, the mutant frequency 8 weeks after treatment was significantly higher (P Ͻ 0.03) support of the in vivo mutagenicity of CP was the cumulative increase in mutant frequency with successive CP doses obtained than that before treatment (two treatments).
increased TG R mutant frequency in blood lymphocytes seen after exposure to CP is largely transient and peaks~2 weeks after exposure. A similar transient pattern has been observed for cells carrying sister chromatid exchanges (SCEs) (Jacobson-Kram et al., 1991) . The reason for disappearance of TG R T-lymphocytes from the blood is not known, but there are several possible explanations. TG R lymphocytes in the blood may be selected against, either because of their HPRT deficiency or because of other genetic damage they have sustained. Alternatively, the TG R lymphocytes may be members of a relatively short-lived pool of blood lymphocytes which is replaced over a period of a few weeks by lymphocytes which were less susceptible to CP-induced mutagenesis at the time of CP treatment. Another explanation for a transient increase in mutant frequency is that it represents the outgrowth of a single clone subsequently selected against. Although this is considered unlikely, it could be investigated by determining the mutational spectra of the lymphocyte populations at (Grant et al., 1999) . A molecular approach is from Sanderson et al. (1991). feasible, since it is expected that a change in the mutational spectra would be observed, as was the case in a transgenic mouse model where the spectrum of hprt mutations in CPfor a patient who received five doses, each 1 month apart. This clear dose-response, shown in Figure 2 , suggests that treated mice was significantly different from that in control mice (Walker et al., 1999) . Both CP and CAB are classified the observed increases were real and induced by treatment. Although unlikely, it is possible that the increases in mutant as carcinogenic to humans (IARC, 1987) . CAB principally induces single base-pair mutants with 64-75% being at G·Cs, frequency were a consequence of an over-representation of existing pre-treatment mutants due to selective cell killing of while CP induces crosslinks and only 22% of monoadducts are at G·Cs (for review see Sanderson and Shield, 1996) . It non-mutant cells by cytotoxic drug treatment. Interestingly, the sensitivity to detect in vivo mutagenesis may depend on should also be possible to compare the mutational spectra of CP and CAB both in vivo and in vitro to elucidate their the target cell type examined. In a mouse model, Gorelick et al. (1999) found significant increases in mutant frequency mechanisms of action further. The transient increases in mutant frequency observed may of the lungs and urinary bladder, but not in bone marrow, kidney or splenic T-lymphocytes.
be related to changes in cell cycling and selection of different classes of T-lymphocytes. CP acts by inhibiting DNA synthesis, Only one of the two patients treated with CAB in this study showed a detectable increase in mutant frequency following principally in the S phase of the cell cycle, causing lymphopenia in both B-and T-lymphocytes. The predominant T-lymphocyte three monthly treatments. Palmer et al. (1986) failed to find a difference in mutant frequency in three patients who had been phenotype changed from CD8 ϩ ,TCRγ/δ ϩ to CD4 ϩ ,TCRα/β ϩ in TG R cell lines from a patient with subacute cutaneous lupus treated with multiple doses of CAB. The earlier study differed from this current study in that patients were not studied after treatment with an intravenous pulse of CP (Wood et al., 1994) . It is suggested that the CD8 ϩ ,TCRγ/δ ϩ subgroup of prospectively, and a different assay for thioguanine resistance, a non-clonal assay, was used. Clearly more patients need to T-lymphocytes rebounds after CP treatment and are implicated in the pathogenesis of the disease and responsible for be studied before conclusions can be drawn about the in vivo effects of CAB. It would be useful to include analysis of postreappearance of symptoms. Regardless of the reason for the disappearance of TG R lymphocytes, this phenomenon may treatment mutational spectra in future studies to aid our understanding of the nature of chlorambucil mutagenesis limit the use of this assay as a method for monitoring individuals for long-term exposure to mutagens. in vivo. This may provide insight into the mechanism underlying the increased risk of leukemia observed following treatInter-individual differences in frequency of mutations induced by CP were observed both in this study and the study ment of non-Hodgkin's lymphoma with CAB. Travis et al. (1994) studied six CAB-treated patients and 22 controls and by Ammenheuser et al. (1988) . In two of six patients in this study and one of six patients in the study by Ammenheuser found risk of acute non-lymphocytic leukemia increased with increasing cumulative dose of CAB, with an overall relative and co-workers, no detectable increase in mutant frequency was induced by similar doses of CP. The lack of mutation risk of 2.4 [95% confidence interval (CI) 0.7-8.6].
The results for CP-treated patients in this study are generally induction in some patients may be due to genetic or other, as yet unknown, differences between individuals. These possiconsistent with those of a prospective study by Ammenheuser et al. (1988) , using an alternative assay for TG R mutants and bilities for difference in mutation sensitivity need to be explored. The ability to induce TG R mutations by in vitro a different monitoring schedule. Those authors reported that five of six patients treated with 750 mg of CP had greater exposure of freshly isolated lymphocytes to CP will allow us to design experiments to define further the nature of intermutant frequencies 2 weeks after therapy, but that the mutant frequencies had returned to normal by 4 weeks after therapy.
individual differences in mutagen susceptibility by studies of lymphocytes from normal individuals. If reproducible differThe results of the current study and the previous study by Ammenheuser et al. (1988) together suggest that the ences in the in vitro susceptibility of lymphocytes from different individuals to CP-induced mutagenesis can be demonstrated, References then such an assay could be tested prospectively to determine Allegretta,M., Albertini,R.J., Howell,M.D., Smith,L.R., Martin,R., its ability to predict both the levels of mutations induced McFarland,H.F., Sriram,S., Brostoff,S. and Steinman,L. (1994) Homologies between T cell receptor junctional sequences unique to multiple sclerosis in vivo and the risk of treatment-related leukemia. The reproand T cells mediating experimental allergic encephalomyelitis. J. Clin. ducibility and reliability of these assays are important if they Invest., 94, [105] [106] [107] [108] [109] are to be used for screening or monitoring. We have shown Ammenheuser,M.M., Ward,J.B.,Jr, Whorton,E.B., Kilian,J.M. and the assay to be consistent for the cell line WIL2-NS over an Legator,M.S. (1988) Elevated frequencies of 6-thioguanine resistant extended period under standard assay conditions (see Table I ).
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